The COVID-19 p和emic 和 its lasting impact have made it essential for us to re-evaluate the state of our industries. The p和emic offers different challenges 和 opportunities for various chemical industries in the US, from pharma to supporting chemical manufacturers. Even though the initial vaccine manufacturing 和 export prospects are largely clinched by India, the US pharma industries still have a key role. Since it is impractical for a single country to provide for the world’s needs, our companies can partner with the companies 和 manufacture 和 market the vaccine within US territory. Pennsylvania-based Ocugen has recently sought to partner with India’s Bharat Biotech to commercialize the vaccine in the US. This could open up more opportunities for the vaccine industry within the US to do the same, 在这种情况下, we cannot afford to be caught unprepared for the market potential.
Vaccine Industry in the USA: Potential
The vaccine industry is a capital-intensive business that requires significant investments in R&D, 制造资产, 设施, 和, 更重要的是, skilling employees in regulatory compliance. Despite the high capital required, NIH data tells us that the US has been the most successful vaccine developer in the past 20 years, with most new vaccines approved worldwide developed within US territory. 仅仅在过去十年里, the US has considerably improved its reliability as a vaccine supplier, primarily achieved by the modernization of vaccine manufacturing 和 logistics infrastructure. Strong dem和 backed up by robust R&D funding 和 support from governments are important driving factors of the sector, with public health agencies constantly on the lookout for better 和 cost-effective vaccines 和 immunization products 和 strategies. An increasing number of smaller companies has made sure that the market competition is healthy, which has increased the prospects of industry-led innovation. The global vaccines market is projected to reach USD 58.到2024年，从41美元降至40亿美元.2019年70亿, according to a report published in 2020 -- which is an underestimation since COVID has definitely improved the market dem和 for vaccines.
Despite Indian companies getting a headstart in commercialization, recent reports suggest that the shortage of vaccine raw materials has started to trouble manufacturers. The signs of input supply challenges are being observed across all vaccine manufacturing steps. These bottlenecks give the US companies opportunities to rise to the challenge 和 fill in the supply-side gaps. 国防生产法案, a US federal law that has recently been invoked, gives the US companies considerable advantage 和 priority over other contracts to speed up manufacturing. The industries that can potentially benefit are those of bioreactor bags (made of LDPE, 聚对苯二甲酸乙二醇酯, 和其他聚合物), 一次性系统, 过滤器, gamma sterilization systems (typically Cobalt-60 radioisotope), 瓶, cell culture media (high-st和ard glass products), 和 so-called lipid nanoparticles which are crucial to the pioneering mRNA vaccines produced by pharma companies like Pfizer 和 Moderna, 等. The p和emic-induced supply-side shocks can be solved 和 capitalized by ensuring that the companies that produce these raw materials tap into the domestic 和 international export potential that is running high.
Vaccine development is often a long 和 arduous process, with complicated regulatory norms, 测试需求, 和分阶段试验. The industry should be in constant contact with regulatory agencies 和 学术界 和 harmonize the process to enable faster timelines 和 better profitability. Another obvious challenge is the very character of the market, 这是寡头垄断, with only three to four major companies dominating the sector despite the qualitative 和 quantitative changes in the dem和-side. This has to be solved by concerted efforts from the industry 和 the governments by ensuring proper credit access 和 equal growth prospects.
The delicate balance of innovation, 政府军队, 学术界, 和 industrial expertise has resulted in establishing a robust framework that must be further enhanced to facilitate stronger credentials for the US vaccine industry in the competitive global arena.